# Bupropion for Depression in ESRD Patients on Hemodialysis

> **NCT02238977** · PHASE4 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 1 (actual)

## Conditions studied

- Major Depression
- End Stage Renal Disease

## Interventions

- **DRUG:** Fluoxetine
- **DRUG:** Bupropion

## Key facts

- **NCT ID:** NCT02238977
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-31
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-03-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study stopped due to difficulty recruiting
- **Last updated:** 2018-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02238977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02238977, "Bupropion for Depression in ESRD Patients on Hemodialysis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02238977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*